Microsize antibodies for $99 | Learn More >>

Human Amino Acid Binding

$293
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunofluorescence (Frozen), Western Blotting

Background: Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the biosynthesis of serotonin (1) by converting tryptophan to 5-hydroxy-L-tryptophan (2). Two isoforms of TPH exist: TPH-1 is mainly expressed in the periphery, whereas the expression of TPH-2 is restricted to neuronal cells and the central nervous system (3). Most of the serotonin found throughout the body is synthesized by TPH-1 in enterochromaffin cells of the gastrointestinal tract. Targeted disruption of the tph1 gene results in low levels of circulating and tissue serotonin (4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: L-DOPA decarboxylase (DDC) is a pyridoxal 5-phosphate (PLP)-dependent enzyme that catalyzes the decarboxylation of L-DOPA to dopamine (1) and L-5HTP to serotonin (2). By catalyzing the reaction to produce dopamine, DDC is involved in many important metabolic processes and plays a central role in the complex neuroendocrine-immune regulatory network (1). DDC is expressed in the central nervous system (3), but has also been detected in some peripheral organs such as the liver and adrenal gland, as well as leukocytes of rat and human (1). DDC is thought to be the sole enzyme responsible for the synthesis of the trace amines 2-phenylethylamine, p-tyramine, and tryptamine, which are considered to act as neuromodulators (2,4). DDC is also regarded as a general biomarker for neuroendocrine tumors (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: β-transducin repeat-containing protein (β-TrCP or FBW1A) is an F-box family protein characterized by the presence of the protein-protein mediating F-box domain first described in cyclin F. F-box proteins act as substrate adaptors that target proteins containing a specific phosphorylated sequence element, referred to as a phosphodegron, to the SCF E3 ubiquitin ligase complex for ubiquitination (1,2). β-TrCP targets many important proteins with diverse functions, such as p53, H-Ras, Smad4, IκBα, β-catenin, and the cell cycle checkpoint protein claspin, for ubiquitin-mediated degradation (3-5). Research studies have shown that inhibition of β-TrCP expression has a demonstrated benefit in the treatment of prostate cancer (6).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: β-transducin repeat-containing protein (β-TrCP or FBW1A) is an F-box family protein characterized by the presence of the protein-protein mediating F-box domain first described in cyclin F. F-box proteins act as substrate adaptors that target proteins containing a specific phosphorylated sequence element, referred to as a phosphodegron, to the SCF E3 ubiquitin ligase complex for ubiquitination (1,2). β-TrCP targets many important proteins with diverse functions, such as p53, H-Ras, Smad4, IκBα, β-catenin, and the cell cycle checkpoint protein claspin, for ubiquitin-mediated degradation (3-5). Research studies have shown that inhibition of β-TrCP expression has a demonstrated benefit in the treatment of prostate cancer (6).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Western Blotting

Background: Tyrosine hydroxylase (TH) catalyzes the rate-limiting step in the synthesis of the neurotransmitter dopamine and other catecholamines. TH functions as a tetramer, with each subunit composed of a regulatory and catalytic domain, and exists in several different isoforms (1,2). This enzyme is required for embryonic development since TH knockout mice die before or at birth (3). Levels of transcription, translation and posttranslational modification regulate TH activity. The amino-terminal regulatory domain contains three serine residues: Ser9, Ser31 and Ser40. Phosphorylation at Ser40 by PKA positively regulates the catalytic activity of TH (4-6). Phosphorylation at Ser31 by CDK5 also increases the catalytic activity of TH through stabilization of TH protein levels (7-9).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: Tyrosine hydroxylase (TH) catalyzes the rate-limiting step in the synthesis of the neurotransmitter dopamine and other catecholamines. TH functions as a tetramer, with each subunit composed of a regulatory and catalytic domain, and exists in several different isoforms (1,2). This enzyme is required for embryonic development since TH knockout mice die before or at birth (3). Levels of transcription, translation and posttranslational modification regulate TH activity. The amino-terminal regulatory domain contains three serine residues: Ser9, Ser31 and Ser40. Phosphorylation at Ser40 by PKA positively regulates the catalytic activity of TH (4-6). Phosphorylation at Ser31 by CDK5 also increases the catalytic activity of TH through stabilization of TH protein levels (7-9).

$269
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Western Blotting

Background: Tyrosine hydroxylase (TH) catalyzes the rate-limiting step in the synthesis of the neurotransmitter dopamine and other catecholamines. TH functions as a tetramer, with each subunit composed of a regulatory and catalytic domain, and exists in several different isoforms (1,2). This enzyme is required for embryonic development since TH knockout mice die before or at birth (3). Levels of transcription, translation and posttranslational modification regulate TH activity. The amino-terminal regulatory domain contains three serine residues: Ser9, Ser31 and Ser40. Phosphorylation at Ser40 by PKA positively regulates the catalytic activity of TH (4-6). Phosphorylation at Ser31 by CDK5 also increases the catalytic activity of TH through stabilization of TH protein levels (7-9).

$293
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: Argininosuccinate synthetase (ASS1) catalyzes the formation of argininosuccinate from citrulline and aspartate, the rate-limiting step in the urea cycle that is responsible for the synthesis of arginine and the clearance of nitrogenous waste (1). ASS1 is ubiquitously and differentially expressed in different cell types and tissues. Mutations in ASS1 are associated with citrullinemia type I, an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels in human patients (2, 3).Loss of ASS1 expression is one of the common metabolic alterations observed in many cancers, and it is a prognostic biomarker of reduced metastasis-free survival. ASS1 deficiency leads to the dependence of extracellular arginine for survival, proliferation, and cell growth. Ariginine starvation induces autophagy and apoptosis in ASS1 deficient cells and this has been exploited as a therapeutic intervention for the tumors with loss of ASS1 expression (4, 5). Pegylated arginine deiminase (ADI-PEG20), an enzyme that degrades arginine into citrulline, causes significant growth inhibition in tumors that have lost ASS1 expression, such as hepatocellular carcinoma, breast cancer, and sarcoma (6-8).

$303
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Arrestin proteins function as negative regulators of G protein-coupled receptor (GPCR) signaling. Cognate ligand binding stimulates GPCR phosphorylation, which is followed by binding of arrestin to the phosphorylated GPCR and the eventual internalization of the receptor and desensitization of GPCR signaling (1). Four distinct mammalian arrestin proteins are known. Arrestin 1 (also known as S-arrestin) and arrestin 4 (X-arrestin) are localized to retinal rods and cones, respectively. Arrestin 2 (also known as β-arrestin 1) and arrestin 3 (β-arrestin 2) are ubiquitously expressed and bind to most GPCRs (2). β-arrestins function as adaptor and scaffold proteins and play important roles in other processes, such as recruiting c-Src family proteins to GPCRs in Erk activation pathways (3,4). β-arrestins are also involved in some receptor tyrosine kinase signaling pathways (5-8). Additional evidence suggests that β-arrestins translocate to the nucleus and help regulate transcription by binding transcriptional cofactors (9,10).

$303
100 µl
APPLICATIONS
REACTIVITY
Hamster, Human

Application Methods: Western Blotting

Background: CrkII, a cellular homologue of v-Crk, belongs to a family of adaptor proteins with an SH2-SH3-SH3 domain structure that transmits signals from tyrosine kinases (1). The primary function of Crk is to recruit cytoplasmic proteins in the vicinity of tyrosine kinases through SH2-phospho-tyrosine interaction. Thus, the output from Crk depends on the SH3-binding proteins, which include the C3G and Sos guanine nucleotide exchange proteins, Abl tyrosine kinase, DOCK180 and some STE20-related kinases. The variety of Crk-binding proteins indicates the pleiotropic function of Crk (2). The two CrkII SH3 domains are separated by a 54 amino acid linker region, which is highly conserved in Xenopus, chicken and mammalian CrkII proteins (3). Tyrosine 221 in this region is phosphorylated by the Abl tyrosine kinase (4), IGF-I receptor (5) and EGF receptor (6). Once Tyr221 is phosphorylated, CrkII undergoes a change in intramolecular folding and SH2-pTyr interaction, which causes rapid dissociation of CrkII from the tyrosine kinase complex (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Western Blotting

Background: CrkII, a cellular homologue of v-Crk, belongs to a family of adaptor proteins with an SH2-SH3-SH3 domain structure that transmits signals from tyrosine kinases (1). The primary function of Crk is to recruit cytoplasmic proteins in the vicinity of tyrosine kinases through SH2-phospho-tyrosine interaction. Thus, the output from Crk depends on the SH3-binding proteins, which include the C3G and Sos guanine nucleotide exchange proteins, Abl tyrosine kinase, DOCK180 and some STE20-related kinases. The variety of Crk-binding proteins indicates the pleiotropic function of Crk (2). The two CrkII SH3 domains are separated by a 54 amino acid linker region, which is highly conserved in Xenopus, chicken and mammalian CrkII proteins (3). Tyrosine 221 in this region is phosphorylated by the Abl tyrosine kinase (4), IGF-I receptor (5) and EGF receptor (6). Once Tyr221 is phosphorylated, CrkII undergoes a change in intramolecular folding and SH2-pTyr interaction, which causes rapid dissociation of CrkII from the tyrosine kinase complex (3).

$262
3 nmol
300 µl
SignalSilence® β-Arrestin 1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit β-arrestin 1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
REACTIVITY
Human

Background: Arrestin proteins function as negative regulators of G protein-coupled receptor (GPCR) signaling. Cognate ligand binding stimulates GPCR phosphorylation, which is followed by binding of arrestin to the phosphorylated GPCR and the eventual internalization of the receptor and desensitization of GPCR signaling (1). Four distinct mammalian arrestin proteins are known. Arrestin 1 (also known as S-arrestin) and arrestin 4 (X-arrestin) are localized to retinal rods and cones, respectively. Arrestin 2 (also known as β-arrestin 1) and arrestin 3 (β-arrestin 2) are ubiquitously expressed and bind to most GPCRs (2). β-arrestins function as adaptor and scaffold proteins and play important roles in other processes, such as recruiting c-Src family proteins to GPCRs in Erk activation pathways (3,4). β-arrestins are also involved in some receptor tyrosine kinase signaling pathways (5-8). Additional evidence suggests that β-arrestins translocate to the nucleus and help regulate transcription by binding transcriptional cofactors (9,10).

$122
20 µl
$293
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunohistochemistry (Paraffin), Western Blotting

Background: Arrestin proteins function as negative regulators of G protein-coupled receptor (GPCR) signaling. Cognate ligand binding stimulates GPCR phosphorylation, which is followed by binding of arrestin to the phosphorylated GPCR and the eventual internalization of the receptor and desensitization of GPCR signaling (1). Four distinct mammalian arrestin proteins are known. Arrestin 1 (also known as S-arrestin) and arrestin 4 (X-arrestin) are localized to retinal rods and cones, respectively. Arrestin 2 (also known as β-arrestin 1) and arrestin 3 (β-arrestin 2) are ubiquitously expressed and bind to most GPCRs (2). β-arrestins function as adaptor and scaffold proteins and play important roles in other processes, such as recruiting c-Src family proteins to GPCRs in Erk activation pathways (3,4). β-arrestins are also involved in some receptor tyrosine kinase signaling pathways (5-8). Additional evidence suggests that β-arrestins translocate to the nucleus and help regulate transcription by binding transcriptional cofactors (9,10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Lysyl-tRNA synthetase (LysRS) is a multifunctional protein that has both regular and mitochondrial forms. The regular form of LysRS belongs to a family of aminoacyl-tRNA synthetases (aaRSs) that catalyze amino acid attachment to its cognate tRNA. In mammalian systems, LysRS forms a multisystem complex (MSC) with several other aaRSs (1-3). In addition to its conventional function, LysRS regulates diadenosine tetraphosphate (Ap4A) production (3). Cellular and metabolic stress increases the level of Ap4A, which functions as a cellular alarm system (3-5). Following FcεRI aggregation in mast cells, MAPK/Erk kinase (MEK) phosphorylates LysRS at Ser207 (5). Serine phosphorylation of LysRS leads to the release of LysRS from MSC and its translocation into the nucleus (5), as well as increased synthesis of Ap4A (5,6). LysRS binds to microphthalmia transcription factor (MITF) and MITF repressor Hint-1. Upon binding of Ap4A, Hint-1 is released from the complex that in turn allows the transcription of MITF-responsive genes (5-7). LysRS is also involved in HIV viral assembly through incorporation into HIV-1 virions via an interaction with HIV-1 Gag (8). Research studies have shown that in the presence of mutant Cu,Zn-superoxide dismutase (SOD1), mitochondrial LysRS tends to be misfolded and degraded by proteasomal degradation, contributing to mitochondrial dysfunction in Amyotrophic Lateral Sclerosis (ALS) (9). LysRS is also secreted and has cytokine-like functions (10). LysRS was also found to be an autoantigen in autoimmune responses (11).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: Lysyl-tRNA synthetase (LysRS) is a multifunctional protein that has both regular and mitochondrial forms. The regular form of LysRS belongs to a family of aminoacyl-tRNA synthetases (aaRSs) that catalyze amino acid attachment to its cognate tRNA. In mammalian systems, LysRS forms a multisystem complex (MSC) with several other aaRSs (1-3). In addition to its conventional function, LysRS regulates diadenosine tetraphosphate (Ap4A) production (3). Cellular and metabolic stress increases the level of Ap4A, which functions as a cellular alarm system (3-5). Following FcεRI aggregation in mast cells, MAPK/Erk kinase (MEK) phosphorylates LysRS at Ser207 (5). Serine phosphorylation of LysRS leads to the release of LysRS from MSC and its translocation into the nucleus (5), as well as increased synthesis of Ap4A (5,6). LysRS binds to microphthalmia transcription factor (MITF) and MITF repressor Hint-1. Upon binding of Ap4A, Hint-1 is released from the complex that in turn allows the transcription of MITF-responsive genes (5-7). LysRS is also involved in HIV viral assembly through incorporation into HIV-1 virions via an interaction with HIV-1 Gag (8). Research studies have shown that in the presence of mutant Cu,Zn-superoxide dismutase (SOD1), mitochondrial LysRS tends to be misfolded and degraded by proteasomal degradation, contributing to mitochondrial dysfunction in Amyotrophic Lateral Sclerosis (ALS) (9). LysRS is also secreted and has cytokine-like functions (10). LysRS was also found to be an autoantigen in autoimmune responses (11).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Arrestin proteins function as negative regulators of G protein-coupled receptor (GPCR) signaling. Cognate ligand binding stimulates GPCR phosphorylation, which is followed by binding of arrestin to the phosphorylated GPCR and the eventual internalization of the receptor and desensitization of GPCR signaling (1). Four distinct mammalian arrestin proteins are known. Arrestin 1 (also known as S-arrestin) and arrestin 4 (X-arrestin) are localized to retinal rods and cones, respectively. Arrestin 2 (also known as β-arrestin 1) and arrestin 3 (β-arrestin 2) are ubiquitously expressed and bind to most GPCRs (2). β-arrestins function as adaptor and scaffold proteins and play important roles in other processes, such as recruiting c-Src family proteins to GPCRs in Erk activation pathways (3,4). β-arrestins are also involved in some receptor tyrosine kinase signaling pathways (5-8). Additional evidence suggests that β-arrestins translocate to the nucleus and help regulate transcription by binding transcriptional cofactors (9,10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: Serine hydroxymethyltransferases 1 and 2 (SHMT1, SHMT2) are cytoplasmic and mitochondrial serine hydroxylmethyltransferases, respectively (1,2). They catalyze the conversion of serine to glycine with the transfer of β-carbon from serine to tetrahydrofolate (THF) to form 5, 10-methylene-THF (1, 2). Research studies indicate that SHMT1 hemizygosity is associated with higher risk of intestinal cancer in mice of a certain genetic background (3). Suppression of SHMT2 was shown to block cell proliferation (4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Arrestin proteins function as negative regulators of G protein-coupled receptor (GPCR) signaling. Cognate ligand binding stimulates GPCR phosphorylation, which is followed by binding of arrestin to the phosphorylated GPCR and the eventual internalization of the receptor and desensitization of GPCR signaling (1). Four distinct mammalian arrestin proteins are known. Arrestin 1 (also known as S-arrestin) and arrestin 4 (X-arrestin) are localized to retinal rods and cones, respectively. Arrestin 2 (also known as β-arrestin 1) and arrestin 3 (β-arrestin 2) are ubiquitously expressed and bind to most GPCRs (2). β-arrestins function as adaptor and scaffold proteins and play important roles in other processes, such as recruiting c-Src family proteins to GPCRs in Erk activation pathways (3,4). β-arrestins are also involved in some receptor tyrosine kinase signaling pathways (5-8). Additional evidence suggests that β-arrestins translocate to the nucleus and help regulate transcription by binding transcriptional cofactors (9,10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: L-type amino acid transporter 1 (LAT1), also known as Solute carrier family 7 member 5 (SLC7A5), is a high-affinity neutral transporter of larger amino acids. It facilitates the cellular amino acid uptake in a sodium independent manner (1-2) and selectively transports D-and L-isomers of small neutral amino acids (3). LAT1 also regulates amino acid exchange in conjunction with solute carrier family 1 member 5 (SLC1A5) (2,4-6). Transport of thyroid hormones across the placenta is established via LAT1 during normal fetal development (7). LAT1 promotes neuronal cell proliferation by regulating the transport of amino acids across the blood brain barrier (8). LAT1 is upregulated in various cancer types including breast cancer, lung cancer, prostate cancer, and gliomas (9,10). High expression of LAT1 is detected in non-small cell lung cancer with lymph node metastases(9,11,12). Increased LAT1 expression is a novel biomarker of high grade malignancy in prostate cancers (12). Inhibition of LAT1 suppresses tumor cell growth in several tumor types (10,13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: SNAT1/SLC38A1 belongs to the system A transporters that mediate Na+-dependent transport of short-chain neutral amino acids such as alanine, serine, and glutamine. SNAT1/SLC38A1 mediates the uptake of glutamine in neurons and plays a crucial role in glutamate-glutamine cycle. Steep concentration gradients across the plasma membrane are achieved by coupling of the electrochemical sodium gradient to amino acid transport. This allows a unidirectional mode of transport for SNAT1/SLC38A1. Upregulation of SNAT1/SLC38A1 by neurotrophic factors is key to dendritic growth and branching of cortical neurons. High expression of SNAT1/SLC38A1 is found in cerebral cortex primarily in neurons and to a lesser extent in astrocytes (1-4). Elevated SNAT1/SLC38A1 expression is prominent in human solid tumors including gliomas, hepatocellular carcinomas and human breast cancer (5-8). Research studies show that an aberrant SNAT1/SLC38A1 expression profile correlates with solid tumor recurrence and poor prognosis in patients with cholangiocarcinoma (9).